Data protection Impressum

Pharma

Global demand for biologics is at an all-time high, and Western Switzerland is positioning itself as a key player in meeting that demand.

Why Switzerland

Biomanufacturing in Western Switzerland

BioAlps, the life sciences cluster of Western Switzerland, offers a dynamic network, an innovative and supportive environment and direct access to the region's vibrant life sciences ecosystem.

BioAlps, Western Switzerland’s life sciences cluster

Vaud-based life sciences company Limula has secured CHF 6.2 million to democratize access to life-saving cell and gene therapies.

Limula secures CHF 6.2 million to advance automated cell therapy platform

21 May 2024

Takeda will receive an exclusive option to license AC Immune's ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer's disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.

AC Immune and Takeda sign USD 100 million deal to treat Alzheimer’s disease

13 May 2024

Ikerian AG, along with its subsidiary RetinAI, has successfully completed a USD 6.18 million Series A extension financing round to propel the development and commercial rollout of innovative medical technologies.

Ikerian, parent company of RetinAI, secures USD 6.18 million for AI-driven medical advancements

13 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2024)

30 April 2024

Takeda Pharmaceutical has announced a CHF 5 million investment in renewable energy for its Neuchâtel facility.

Takeda commits CHF 5 million to renewable energy for its Neuchâtel site

29 April 2024

Risklick, a spin-off from the University of Bern, has unveiled its cutting-edge software, Protocol AI, designed to transform the landscape of pharmaceutical development.

UniBe spin-off Risklick unveils AI tool to streamline clinical trials

29 April 2024

The newly released Swiss Biotech Report 2024 highlights an exceptional year for the Swiss biotech industry, marking a record CHF 7.3 billion in revenues and over CHF 2 billion in capital investments.

The Swiss biotech industry: reliable partners beyond borders

23 April 2024

1 2 3 4 5 6 7 … 13